Antitrust: Commission confirms unannounced inspections in pharmaceutical sector


On 30 November 2010, European Commission officials carried out unannounced inspections at the premises of a number of pharmaceutical companies in several Member States. Reason was the Commission's suspicion that they may have acted individually or jointly, notably, to delay generic entry for a particular medicine.

Restrictive business practices and/or the abuse of a dominant market position are prohibited under EU antitrust law (Articles 101 and 102 EU Treaty). The companies in question risk fines and other sanctions if the Commission's allegations are confirmed. EU law provides for a procedure, including rights of defence, allowing the companies at risk to present their position.

LOADING PDF: If there are any problems, click here to download the file.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Peter Kugel, KUGEL LEGAL - European Chemical Law Attorneys | Attorney Advertising

Written by:


KUGEL LEGAL - European Chemical Law Attorneys on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:

Sign up to create your digest using LinkedIn*

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.

Already signed up? Log in here

*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.